A clinical validation study confirmed the high accuracy of BIOHIT Oyj’s new generation GastroPanel test for the diagnosis of atrophic gastritis (AG) and Helicobacter pylori infection in patients referred for gastroscopy.
This unique blood test is designed for the first-line diagnosis of H. pylori infection and AG in patients with upper abdominal symptoms, such as dyspepsia and gastro-oesophageal reflux disease (GORD), before endoscopy. GastroPanel is also the only test on the market capable of monitoring the regulatory mechanism of acid output in the stomach.
The new generation (unified) GastroPanel test works on the same principle as the original GastroPanel enzyme-linked immunosorbent assay (ELISA) test and is designed to harmonise the ELISA processing conditions of four biomarkers. This highly informative assay is therefore a cost-effective solution for population-based screening for the risk of gastric cancer in asymptomatic and symptomatic individuals, and its efficacy has already been confirmed by several studies in both high- and low-risk countries.
This latest study evaluated the diagnostic accuracy of the new-generation GastroPanel test for the diagnosis of both AG and H. pylori infection in patients referred for gastroscopy from primary care with different indications. Along with previously published clinical validation studies, this biopsy-confirmed study was designed to verify the diagnostic capabilities of the new-generation GastroPanel test compared to the current gold standard (gastroscopy and biopsy analysis), and to demonstrate its performance was comparable to the original GastroPanel test. The positive results from this study also pave the way for BIOHIT’s new GastroPanel Quick Test (point-of-care test) which will be launched in early in 2022.
www.biohithealthcare.co.uk/gastropanel.
